eTable. Long-term results (international data: ISHLT Registry 1995–2012 [6]; national data [Germany]: AQUA Institute 2008–2012).
| a) Recipient survival according to underlying disease | ||||||||||
| ISHLT Registry | ||||||||||
| Survival rate (%) | ||||||||||
| Diagnosis | n | 1 Year | 3 Years | 5 Years | 10 Years | |||||
| COPD | 12 914 | 82.1% | 65.7% | 52.4% | 25.8% | |||||
| Idiopathic pulmonary fibrosis | 8528 | 74.7% | 59.2% | 46.9% | 24.4% | |||||
| Cystic fibrosis | 6164 | 82.9% | 69.3% | 59.6% | 43.5% | |||||
| α 1-Antitrypsin deficiency | 2624 | 79.1% | 65.4% | 56.4% | 34.5% | |||||
| Idiopathic PAH | 1400 | 70.9% | 59.4% | 50.9% | 35.6% | |||||
| Sarcoidosis | 934 | 74.2% | 60.0% | 52.9% | 31.2% | |||||
| AQUA Institute | ||||||||||
| Survival rate (%) | ||||||||||
| Diagnosis | n | 1 Year | 3 Years | 5 Years | 10 Years | |||||
| Obstructive lung disease (COPD, α 1-antitrypsin deficiency, bronchiectasis) | 400 | 79.8% | 59.1% | – | – | |||||
| Restrictive lung disease (idiopathic pulmonary fibrosis) | 296 | 70.9% | 60.3% | – | – | |||||
| Pulmonary hypertension (PAH and Eisenmenger syndrome) | 58 | 77.6% | 57.9% | – | – | |||||
| Cystic fibrosis | 190 | 78.9% | 57.6% | – | – | |||||
| Other (incl. lymphangioleiomyomatosis, sarcoidosis and re-transplantations) | 167 | 70.7% | 56.6% | – | – | |||||
| AQUA, Institute for Applied Quality Improvement and Research in Health Care (Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen); COPD, chronic obstructive pulmonary disease; ISHLT, International Society for Heart and Lung Transplantation; PAH, pulmonary arterial hypertension; n, number of patients | ||||||||||
| b) Causes of death after lung transplantation in adults | ||||||||||
| 0–30 Days | 31 Days–1 Year | 1–3 Years | 3–5 Years | 5–10 Years | ||||||
| ISHLT Registry | n = 2725 | n = 4737 | n = 4315 | n = 2449 | n = 2892 | |||||
| AQUA Institute | n = 125 | n = 108 | – | – | – | |||||
| BOS | 0.3% | 4.6% | 25.9% | >29.0% | 25.4% | |||||
| – | – | – | – | – | ||||||
| Acute rejection | 3.4% | 1.8% | 1.5% | 0.7% | 0.6% | |||||
| 1% | 4% | – | – | – | ||||||
| Malignant tumors | 0.2% | 5.1% | 9.4% | 12.4% | 15.0% | |||||
| – | – | – | – | – | ||||||
| Infection | 19.6% | 38.0% | 23.5% | 19.5% | 18.2% | |||||
| 14% | 35% | – | – | – | ||||||
| Transplant failure | 24.7% | 16.7% | 18.7% | 18.0% | 17.8% | |||||
| 13% | 4% | – | – | – | ||||||
| Cardiovascular | 10.9% | 4.8% | 4.1% | 4.9% | 5.1% | |||||
| 8% | 1% | – | – | – | ||||||
| Technical | 11.0% | 3.4% | 0.9% | 0.6% | 0.8% | |||||
| 2% | 6% | – | – | – | ||||||
| Other | 29.8% | 25.6% | 16.0% | 15.1% | 17.0% | |||||
| 36% | 48% | – | – | – | ||||||
| Multiorgan failure | – | – | – | – | – | |||||
| 26% | 2% | – | – | – | ||||||
| ISHLT, International Society for Heart and Lung Transplantation; AQUA, Institute for Applied Quality Improvement and Research in Health Care (Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen); BOS, bronchiolitis obliterans syndrome; n, number of patients | ||||||||||
At present, 45 centers report their data directly by entering data manually on the ISHLT’s web-based data input system. In addition, the following organizations input information from 345 participating institutes into the ISHLT data system
- United Network for Organ Sharing (United States of America)
- Eurotransplant (Germany, Austria, Belgium, Luxembourg, Netherlands, Slovenia)
- Organizacion Nacional de Trasplantes (Spain)
- Registro Español de Trasplante Cardíaco (Spain)
- UK Transplant (United Kingdom, Ireland)
- Scandia Transplant (Sweden, Norway, Denmark, Finland)
- Australia and New Zealand Cardiothoracic Organ Transplant Registry (Australia, New Zealand)
- Agence de la biomédecine (France)